After completing degrees in Chemistry and Biological Sciences in 2008, Rachel undertook her PhD studies in the group of Prof. Dr. Chang-Chun Ling at the University of Calgary (Canada). Her studies were focused on developing D-idopyranoside chemistry and using these methods toward generating a conjugate vaccine against Campylobacter jejuni, as well as developing inhibitors of Clostridium difficile toxins TcdA and TcdB. In November 2013, Rachel joined the group of Prof. Dr. Beat Ernst as a postdoctoral researcher, leading a new project to help elucidate the role of siglecs in diabetes and also contributing to the ongoing bacterial adhesin FimH project. In January 2015 she was promoted to a Research Associate, and since January 2017 has been working with Prof. Dr. Daniel Ricklin on therapeutic modulation of the complement-mediated immune pathway.